Utilization of antiparkinson drugs in Norway, Sweden, Denmark and Finland 1975-1979.
Defined daily doses per day and 10(3) inhabitants [Formula: see text] of the different types of antiparkinson agents have been compared in the period 1975-1979 for Norway, Sweden, Denmark and Finland. A marked increase in the utilization of L-DOPA containing drugs has taken place especially in Sweden following the introduction of the "combined drugs" (L-DOPA + decarboxylase inhibitor). Statistically, nearly all patients with parkinsonism in Sweden have since 1977 been treated with L-DOPA, while in the other nordic countries about 10% of the patients are not on this therapy. These data are discussed in relation to the current concept of pharmacotherapy of parkinsonism. Further, many patients treated with neuroleptic drugs do in addition take anticholinergic agents. Drug utilization figures indicate this method of treatment to be most common in Denmark and Sweden.
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D003718:Denmark; D004363:Drug Utilization; D005387:Finland; D006801:Humans; D009664:Norway; D013548:Sweden
D000978:Antiparkinson Agents